Genocea Biosciences Inc. (GNCA)

2.25
0.02 0.90
NASDAQ : Health Technology
Prev Close 2.23
Open 2.25
Day Low/High 2.21 / 2.29
52 Wk Low/High 1.99 / 11.28
Volume 81.23K
Avg Volume 120.20K
Exchange NASDAQ
Shares Outstanding 26.15M
Market Cap 58.84M
EPS -2.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Genocea Presents Preclinical Research That Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses At Society For Immunotherapy Of Cancer (SITC)

Genocea Presents Preclinical Research That Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses At Society For Immunotherapy Of Cancer (SITC)

     Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm positive GEN-009 clinical immunogenicity results CAMBRIDGE, Mass.

Genocea Provides Corporate Update And Reports Third Quarter 2019 Financial Results

Genocea Provides Corporate Update And Reports Third Quarter 2019 Financial Results

Generated unprecedented 98% GEN-009 immune response frequency with ATLAS™ Continued advancement of GEN-011, expect to file an IND in first half of 2020 Entered into a common stock purchase agreement for up to $30M with Lincoln Park Capital Conference call...

Genocea Announces Poster Presentation At The European Society For Medical Oncology (ESMO) Congress 2019 In Barcelona And Presentation At An Upcoming Investor Conference

Genocea Announces Poster Presentation At The European Society For Medical Oncology (ESMO) Congress 2019 In Barcelona And Presentation At An Upcoming Investor Conference

Additional p ositive GEN-009 c linical i mmunogenicity d ata d riven by ATLAS™ to be p resented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass.

Genocea To Present At September Healthcare Conferences

Genocea To Present At September Healthcare Conferences

CAMBRIDGE, Mass., Aug.

Genocea Provides Corporate Update, Including Second-Quarter 2019 Financial Results

Genocea Provides Corporate Update, Including Second-Quarter 2019 Financial Results

Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009; Plans to present additional GEN-009 immunogenicity data at ESMO 2019 Conference call today at 8:30 am ET CAMBRIDGE, Mass.

Genocea To Host Quarterly Corporate Update Conference Call & Webcast On July 25th At 8:30 Am ET

Genocea To Host Quarterly Corporate Update Conference Call & Webcast On July 25th At 8:30 Am ET

CAMBRIDGE, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.

NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences' Board Of Directors

NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences' Board Of Directors

Follows NEA investment in Genocea during January 2018 concurrent equity financings

Short Interest In Genocea Biosciences Drops 31.7%

Short Interest In Genocea Biosciences Drops 31.7%

The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 689,309 share decrease in total short interest for Genocea Biosciences Inc , to 1,488,114, a decrease of 31.66% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

GENOCEA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 In Genocea Biosciences, Inc. To Contact The Firm

GENOCEA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 In Genocea Biosciences, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Genocea Biosciences, Inc.

Scott+Scott, Attorneys At Law, LLP Reminds Investors That The Lead Plaintiff Deadline In Genocea Biosciences, Inc. (GNCA) Class Action Is January 2nd

Scott+Scott, Attorneys At Law, LLP Reminds Investors That The Lead Plaintiff Deadline In Genocea Biosciences, Inc. (GNCA) Class Action Is January 2nd

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is reminding investors that a class action has been filed against Genocea Biosciences, Inc.

Scott+Scott, Attorneys At Law, LLP Filed Class Action Against Genocea Biosciences, Inc. (GNCA) - Lead Plaintiff Deadline Is January 2nd

Scott+Scott, Attorneys At Law, LLP Filed Class Action Against Genocea Biosciences, Inc. (GNCA) - Lead Plaintiff Deadline Is January 2nd

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, has filed a class action against Genocea Biosciences, Inc.

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Genocea Bioscience, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Genocea Bioscience, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of...

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Genocea Biosciences, Inc. Shareholders And A Lead Plaintiff Deadline Of January 2, 2018

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Genocea Biosciences, Inc. Shareholders And A Lead Plaintiff Deadline Of January 2, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Genocea Biosciences, Inc.

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Genocea Biosciences, Inc. Investors (GNCA)

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Genocea Biosciences, Inc. Investors (GNCA)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Genocea Biosciences, Inc.

GNCA INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Genocea Biosciences, Inc. And A Lead Plaintiff Deadline Of January 2, 2018

GNCA INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Genocea Biosciences, Inc. And A Lead Plaintiff Deadline Of January 2, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Genocea Biosciences, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 2, 2018

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Genocea Biosciences, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 2, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Genocea Biosciences, Inc.

The Klein Law Firm Announces A Class Action Filed On Behalf Of Genocea Biosciences, Inc. Shareholders And A Lead Plaintiff Deadline Of January 2, 2018

The Klein Law Firm Announces A Class Action Filed On Behalf Of Genocea Biosciences, Inc. Shareholders And A Lead Plaintiff Deadline Of January 2, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Genocea Biosciences, Inc.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Genocea Bioscience, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Genocea Bioscience, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Genocea Biosciences, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 2, 2018

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Genocea Biosciences, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 2, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Genocea Biosciences, Inc.